Bianchi Marco Emilio Professore ordinarioMedicineBIO/11

Born in Milano (Italy), November 18, 1957.
Italian citizen. Two children.

Languages spoken: Italian (mother tongue), English (fluently), German (working knowledge), French (working knowledge).

Education and Professional Experience
October 1980:  “Laurea” in Biological Sciences, summa cum laude, University of Milano (Italy) with the thesis “Physiology and Genetics of the Resistance to the Mn2+ Ion in the Yeast Saccharomyces cerevisiae”.

October 1981 – September 1983:  Postdoctoral Associate in Dr. Charles Radding’s laboratory, Yale University School of Medicine, Department of Human Genetics, 333 Cedar Street, New Haven, CT 06510, USA.

October 1983 – June 1986:  Postdoctoral Fellow of the Italian National Research Council (CNR). University of Milano, Department of Genetics and Microbiology, via Celoria 26, 20133 Milano, Italy.

July 1986 – February 1989:  Staff Scientist, European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, D-6900 Heidelberg, Germany.

November 1987 – October 1992:  Associate Professor of Microbiology, Department of Genetics and Microbiology, University of Pavia, via Abbiategrasso 207, 27100 Pavia, Italy.

November 1992 – October 1999:  Associate Professor of Microbiology, Department of Genetics and Microbiology, University of Milano, via Celoria 26, 20133 Milano, Italy

November 1999 – November 2000:  Associate Professor of Microbiology, Faculty of Medicine, San Raffaele University, via Olgettina 58, 20132 Milano, Italy.

November 2000 – March 2005: Vice-Director for Basic Research, San Raffaele Research Institute, via Olgettina 58, 20132 Milano, Italy.

November 2000 – currently: Professor of Molecular Biology, Faculty of Medicine, San Raffaele University, via Olgettina 58, 20132 Milano, Italy.

July 2007 – Founder of HMGBiotech (http://www.hmgbiotech.com), a biotech company that provides materials and services related to HMGB1.

Honors:       EMBO member (1999, for life). Past member of the Grants Committee of the Human Frontiers Science Program (HFSP), and past Chairman of the Fellowship Committee of the Armenise-Harvard Foundation. Associate editor of the Journal of Leukocyte Biology, BMC Molecular Biology and the Journal of Biology.

136 publications. H factor is 51.

10 most significant publications 2001-2010
Maroso M, Silvia Balosso S, Ravizza T, Liu J, Aronica E, Iyer AM, Rossetti C, Molteni M, Casalgrandi M, Manfredi AA, Bianchi ME and Vezzani A. Toll-Like Receptor 4 (TLR4) and High Mobility Group Box 1 (HMGB1) are involved in ictogenesis and can be targeted to reduce seizures (2010) Nature Medicine 16: 413-9
Yanai H, Ban T, Wang ZC, Choi MK, Kawamura T, Negishi H, Nakasato M, Lu Y, Hangai S, Koshiba , Savitsky D, Ronfani L, Akira S, Bianchi ME, Honda K, Tamura T, Kodama T and Taniguchi T (2009) HMGB proteins function as universal sentinels for nucleic acid-mediated innate immune responses. Nature 462: 99-104
Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P and Bianchi ME (2008) A soluble form of the Receptor for Advanced Glycation Endproducts (RAGE) is produced by proteolytic cleavage of the membrane bound form by the sheddase A Disintegrin and Metalloprotease 10 (ADAM10). FASEB J 22: 3716-27
Palumbo R, Galvez BG, Pusterla T, De Marchis F, Cossu G, Marcu KB and Bianchi ME (2007) Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kB activation. J Cell Biol 19: 33-40
Bianchi ME and Manfredi AA. (2007) High Mobility Group Box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 220: 35-46 (review)
Bosisio D, Marazzi I, Agresti A, Shimizu N, Bianchi ME* and Natoli G* (2006) A hyper-dynamic equilibrium between promoter-bound and nucleoplasmic dimers controls NF-kB-dependent gene activity. EMBO J 25: 798-810 (*co-corresponding)
Bianchi ME and Agresti A (2005) HMG proteins: dynamic players in gene regulation and differentiation. Curr Op Gen Dev 15:496-506 (review)
Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A, Cossu G and Bianchi ME. (2004) Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 164: 441-9
Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A and Bianchi ME (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22: 5551-60
Scaffidi P, Misteli T and Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-5

3 most significant patents 2001-2010
Barone DG, Bianchi ME, Bucci EM, Fumero S (2005) Therapeutic agents for the treatment of  HMGB1-related pathologies. Publication number WO 2006/002971. Granted in the EU (EP 1 768 677 B1)
Bianchi ME, Manfredi A (2003) Use of HMGB1 for the activation of dendritic cells. Publication number WO 03/026691. Granted in the EU (EP 1 432 441 B1) and Australia (Number 2002341266)
Bianchi ME, Bonaldi T, Scaffidi P, Müller, S, Degryse B (2002) HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases. Publication number WO 02/074337. Granted in Italy and Australia.